Nebivolol Sandoz

Nebivolol, the active ingredient in Nebivolol Sandoz, is a beta‑adrenergic blocker presented as an oral tablet for oral administration. It selectively antagonizes β1‑adrenergic receptors and provides nitric‑oxide mediated vasodilation, helping to reduce elevated blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Nebivolol Sandoz as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with assured quality and regulatory conformity. The supply chain adheres to stringent temperature and humidity controls, and the product is manufactured under EU GMP standards.

Nebivolol is used in the management of cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.

Hypertension: Reduces systolic and diastolic blood pressure in adults with essential hypertension. Heart failure (NYHA class II): Improves left ventricular ejection fraction and reduces symptoms in patients with mild to moderate heart failure. Left ventricular systolic dysfunction: Enhances cardiac output and may delay disease progression in patients with reduced ejection fraction.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache reported. - Dizziness: transient light‑headedness, especially after dose initiation. - Fatigue: general tiredness or reduced energy. - Nausea: occasional stomach upset. - Nasal congestion: mild nasal stuffiness. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe bradycardia: markedly reduced heart rate requiring medical attention. - Hypotension: significant drop in blood pressure leading to fainting. - Heart block: atrioventricular conduction disturbances. - Bronchospasm: respiratory difficulty in susceptible individuals. - Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use.

Blood pressure monitoring: Regularly assess blood pressure to avoid excessive hypotension. Cardiac function assessment: Evaluate heart rate and ECG, especially in patients with conduction disorders. Asthma or COPD caution: Use with care in patients with reactive airway disease due to potential bronchoconstriction. Abrupt discontinuation: Do not stop therapy suddenly; taper dose to prevent rebound hypertension. Renal impairment adjustment: Dose may need modification in patients with severe renal dysfunction. Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Nebivolol can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers: Combined use may cause excessive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): May increase nebivolol plasma levels and cardiac depression. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): Can raise nebivolol concentrations, enhancing adverse effects. - Non‑selective β‑blockers: Additive β‑blocking effects leading to severe cardiovascular depression. - Antihypertensive combinations: Concurrent use with multiple agents may cause profound hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: May potentiate hypotensive effect; monitor electrolytes and blood pressure. - ACE inhibitors/ARBs: Combined therapy may increase risk of symptomatic hypotension. - NSAIDs: Can blunt antihypertensive response; observe blood pressure control. - Antidiabetic drugs: Nebivolol may mask hypoglycemia symptoms; check glucose levels. - Digoxin: Possible increase in serum digoxin concentrations; monitor for toxicity.